Form 4: Fulcrum Therapeutics Director Alan Ezekowitz Reports Stock Option Grant

Director Alan Ezekowitz reports the acquisition of stock options in Fulcrum Therapeutics.

Summary

• Alan Ezekowitz, a director of Fulcrum Therapeutics, reported a transaction involving derivative securities.
• On June 17, 2024, Ezekowitz acquired stock options (right to buy) for 30,000 shares of common stock at an exercise price of $7.
• The options vest on the first anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
• Following the transaction, Ezekowitz directly owns 30,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, with neutral sentiment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.

Key Dates